New York · Nonprofit
CANCER RESEARCH INSTITUTE INC
CANCER RESEARCH INSTITUTE INC (New York) receives grants from 485 organizations whose IRS filings report $92,992,979 to it, the largest being ANNA-MARIA AND STEPHEN KELLEN FOUNDATION INC ($27,340,000). 260 of them have funded it in more than one year.
- Revenue FY2025
- $35M
- Funders on record
- 485
- Grants received
- $93M
- Net assets
- $85M
What Cancer Research Institute Inc does
Mission
See schedule ocri is a nonprofit organization dedicated to advancing cancer immunotherapy through scientific discovery and global collaboration. Since 1953, cri has funded research that deepens understanding of the immune system and its role in cancer, leading to breakthroughs such as checkpoint blockade and cell-based therapies. Through investments in science, data, and the research community, cri works to translate discoveries into effective treatments for patients.
As stated on its FY2025 Form 990.
Programs
Research: career development awards + translational innovation and clinical impact awards - see schedule ocri supports world-class scientists across career stages to drive discovery in cancer immunology and immunotherapy. Career development awards, including postdoctoral fellowships and the lloyd j. Old star program, provide flexible, multi-year funding to emerging and established investigators pursuing high-impact, innovative research. Awards range from approximately $243,000 over three years for fellowships to $1.25 million over five years for stars. Translational innovation and clinical impact awards, including clip (clinic and laboratory integration program) grants (up to $300,000 over two years) and technology impact awards (up to $300,000 over two years) support projects that deepen understanding of tumor-immune interactions and advance new immunotherapeutic strategies toward clinical application.
$25,787,340 spentof which $21,770,136 as grants$907,299 earned by the program77% of program spendingClinical - see schedule ocri accelerates the development of promising immunotherapies through early-phase clinical research and collaborative trials. The clinical innovator program supports novel clinical studies with funding of up to $1 million per trial, while the clinical accelerator is an actively managed venture philanthropy program that designs and conducts data-driven, multi-partner clinical studies in areas of high unmet need.
$4,446,746 spentof which $4,202,418 as grants13% of program spendingData - see schedule ocri advances the use of data to enable discovery, translation, and cross-study learning in immunotherapy research. Through support for data resources, analytic tools, and community guidance, cri supports initiatives that improve data quality, standardization, and interoperability across the field. These efforts help unlock insights into response and resistance and guide more effective development of immunotherapies.
$2,851,974 spentof which $2,554,531 as grants9% of program spendingPatient & policy:cri provides education and engagement to improve patient understanding of immunotherapy and support informed decision-making. Through digital content, events, and media outreach, cri reaches patients, caregivers, and stakeholders with accessible scientific and medical information, including resources in multiple languages. Cri also contributes to field-building by convening stakeholders and supporting efforts that improve access to and delivery of immunotherapies.
$290,903 spent1% of program spending
The 4 programs described on its FY2024 Form 990, listed largest first by expense. Program spending in total: $33,376,963.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2020 to 2021, from $127M to $147M (+16%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
Government-grant reliance: 2022 2%. Grants only. Government contracts and fees sit inside program revenue.
75% of CANCER RESEARCH INSTITUTE INC’s revenue is contributions — more reliant on donations than three-quarters of its peers (7% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 6 of the last 9 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Chief executive
Alicia Zhou Start 82024
Chief executive officer
As listed on its FY2025 Form 990.
Who funds it, year by year
2017 → 2023: the base broadened from 106 funders to 185 funders, grant income rose $7.7M → $12M.
47 of 485 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 19% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of CANCER RESEARCH INSTITUTE INC’s funders (the co-funder graph). Top 30 of 485 funders by total. Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
CANCER RESEARCH INSTITUTE INC has a broad base — no single funder exceeds 29% of grant income, and it takes 4 funders to reach half.
the vertical line marks half of all grant income — 4 funders to its left
27% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund CANCER RESEARCH INSTITUTE INC.
Largest funder’s share by year: 2017 66% · 2018 62% · 2019 50% · 2020 46% · 2021 22% · 2022 19% · 2023 25% — diversifying over time.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How long its funders stay
42% of CANCER RESEARCH INSTITUTE INC's funders are still giving 3 years after their first grant; 54% give in more than one year at all.
Share of funders still giving k years after their first recorded grant, pooled across every acquisition cohort. A funder counts as retained in a year only if it made a grant that year. Measured to FY2023, the last fiscal year that has finished arriving — a funder cannot be counted as lapsed in a year most filers have not reached.
Where its funders are
72% of CANCER RESEARCH INSTITUTE INC's grant income comes from New York funders.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $17M arriving through sponsors registered in 20 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
CANCER RESEARCH INSTITUTE INC is better cushioned than half of the 2,969 health nonprofits its size.
this organization peer median middle 50% of peers· 2,969 health nonprofits $10M–$100M, FY2025
Organizations like CANCER RESEARCH INSTITUTE INC
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In New York
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
79% of spending goes to programs.
Governance
Public support
88%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Files a return copy in 51 states
Screen this organization
A dated, signed PDF of the compliance screen for CANCER RESEARCH INSTITUTE INC: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds CANCER RESEARCH INSTITUTE INC?
- CANCER RESEARCH INSTITUTE INC (New York) receives grants from 485 organizations whose IRS filings report $92,992,979 to it, the largest being ANNA-MARIA AND STEPHEN KELLEN FOUNDATION INC ($27,340,000). 260 of them have funded it in more than one year.
- How many funders does CANCER RESEARCH INSTITUTE INC have?
- IRS filings report 485 organizations giving $92,992,979 in grants to CANCER RESEARCH INSTITUTE INC, 260 of which have funded it in more than one year.
- Who is the largest funder of CANCER RESEARCH INSTITUTE INC?
- ANNA-MARIA AND STEPHEN KELLEN FOUNDATION INC is the largest funder on record, with $27,340,000 in grants. The full list of funders is on this page.
- How can an organization like CANCER RESEARCH INSTITUTE INC find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in New York. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2025 (financials across 2017–2025), and the filings of 485 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 22, 2026. What this page cannot tell you · view filing